MPC Therapeutics SA

MPC Therapeutics specializes in mitochondrial research and is developing innovative solutions to rejuvenate tissues. The company's current focus is on the development of small molecules targeting the Mitochondrial Pyruvate Carrier (MPC). These molecules have demonstrated the ability to enhance immune cell function and significantly improve cell-based therapies for cancer. Additionally, they have shown promising results in promoting neurogenesis in preclinical models, with notable implications for Alzheimer's disease.

Founded as a spin-off from the laboratory of Prof. Jean-Claude Martinou, a renowned expert in mitochondrial biology at the University of Geneva, MPC Therapeutics is the first Swiss company to join JLABS, the incubator of Johnson & Johnson.